Domenico Mastrolitto, Executive Director at Campus Bio-Medico Spa and Giovanni Scanagatta, Professor of Economic and Monetary Policy at the University of Rome “La Sapienza” analyze the features of the vaccination plan of the European Union and the strengths of Italian pharmaceutical industry. <\/p>\n\n\n\n
The pharmaceutical multinationals have imposed their conditions, the heavy bureaucracy has slowed down the processes and Europe, although owns global pharmaceutical giants, has not been able to start independent production. <\/p>\n\n\n\n
The delay of vaccination campaigns has also forced some countries to individual behavior, such as the ban on exports and the drive to national production, as in the case of Italy with the new government Draghi. <\/p>\n\n\n\n